Literature DB >> 1976462

Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product.

E Pócsik1, R Mihalik, E Gyódi, M Réti, K Pálóczi, G G Petrányi, M Benczúr.   

Abstract

After platelet allotransfusion, we found a characteristic increase in the expression of interleukin-2 receptor, dipeptydilpeptidase IV (CD26), activation-inducer molecule (AIM, CD69) and transferrin receptors (CD71) on day 3 indicating that important functional molecules expressed on the activation of lymphocytes by allogeneic platelets. At the same time, no consistent increase of other activation molecules such as Ki-l (CD30), intercellular adhesion molecule (ICAM-1, CD54) and Ki-24 (CDw70) antigen expression was detected, probably as a result of the selective activation of some lymphocyte subsets. In order to obtain further evidence for the in vivo activation triggered by allogeneic platelets, subsequent step of T cell activation towards differentiation was investigated with monoclonal antibodies to leucocyte common antigens. A sharp expression of the UCHL1, coupled with a decrease of the CD45R molecule was detected on day 7 or 14, suggesting a T cell priming.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976462      PMCID: PMC1535151          DOI: 10.1111/j.1365-2249.1990.tb05411.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  The influence of the pattern of inflammation and administration of steroids on class II MHC antigen expression in renal transplants.

Authors:  P Häyry; E von Willebrand
Journal:  Transplantation       Date:  1986-10       Impact factor: 4.939

2.  Phenotype versus immunoglobulin and T-cell receptor genotype of Hodgkin-derived cell lines: activation of immature lymphoid cells in Hodgkin's disease.

Authors:  M H Falk; H Tesch; H Stein; V Diehl; D B Jones; C Fonatsch; G W Bornkamm
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

3.  Antigen reactive memory T cells are defined by Ta1.

Authors:  D A Hafler; D A Fox; D Benjamin; H L Weiner
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

Review 4.  Differentiation-linked leukemogenesis in lymphocytes.

Authors:  M F Greaves
Journal:  Science       Date:  1986-11-07       Impact factor: 47.728

5.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).

Authors:  S D Marlin; T A Springer
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

6.  Expression of HLA-DR antigens on peripheral blood T lymphocytes and renal graft tubular epithelial cells in association with rejection.

Authors:  F C Henny; J J Weening; W M Baldwin; P J Oljans; H J Tanke; L A van Es; L C Paul
Journal:  Transplantation       Date:  1986-11       Impact factor: 4.939

7.  Towards a better definition of human leucocyte surface molecules.

Authors:  W Knapp; P Rieber; B Dörken; R E Schmidt; H Stein; A E vd Borne
Journal:  Immunol Today       Date:  1989-08

8.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.

Authors:  R Rothlein; M L Dustin; S D Marlin; T A Springer
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

9.  Functional characterization of an antigen involved in an early step of T-cell activation.

Authors:  M E Cosulich; A Rubartelli; A Risso; F Cozzolino; A Bargellesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Induction of T cell function via the gp33/27 activation inducer molecule (AIM) requires co-expression of the CD3/TcR complex.

Authors:  M Rincón; M Cebrián; F Sánchez-Madrid; M López-Botet
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

View more
  1 in total

1.  The pattern of cytokine gene expression in human colorectal carcinoma.

Authors:  Anna Csiszár; Tamás Szentes; Bea Haraszti; Annamária Balázs; Gyôzô G Petrányi; Eva Pócsik
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.